USD 0.59
(-0.45%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.09 Million USD | -65.62% |
2022 | 3.18 Million USD | 9464.1% |
2021 | 33.33 Thousand USD | -78.95% |
2020 | 158.33 Thousand USD | 75.93% |
2019 | 90 Thousand USD | -24.84% |
2018 | 119.75 Thousand USD | -20.0% |
2017 | 149.68 Thousand USD | 0.0% |
2016 | - USD | -100.0% |
2015 | 194.49 Thousand USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - USD | 100.0% |
2024 Q2 | - USD | 0.0% |
2023 Q1 | 1.09 Million USD | 3.1% |
2023 Q2 | - USD | -100.0% |
2023 Q4 | -1.09 Million USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 FY | 1.09 Million USD | -65.62% |
2022 Q2 | 1.06 Million USD | 0.0% |
2022 Q1 | - USD | 100.0% |
2022 FY | 3.18 Million USD | 9464.1% |
2022 Q4 | 1.06 Million USD | 0.05% |
2022 Q3 | 1.06 Million USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q4 | -33.3 Thousand USD | 0.0% |
2021 FY | 33.33 Thousand USD | -78.95% |
2021 Q2 | - USD | -100.0% |
2021 Q1 | 33.33 Thousand USD | -46.67% |
2020 FY | 158.33 Thousand USD | 75.93% |
2020 Q3 | 95.83 Thousand USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q1 | - USD | 100.0% |
2020 Q4 | 62.5 Thousand USD | -34.78% |
2019 Q3 | - USD | -100.0% |
2019 Q1 | - USD | 100.0% |
2019 FY | 90 Thousand USD | -24.84% |
2019 Q4 | -89.81 Thousand USD | 0.0% |
2019 Q2 | 89.81 Thousand USD | 0.0% |
2018 Q4 | -119.75 Thousand USD | 0.0% |
2018 FY | 119.75 Thousand USD | -20.0% |
2018 Q3 | - USD | -100.0% |
2018 Q1 | 29.93 Thousand USD | -33.33% |
2018 Q2 | 89.81 Thousand USD | 200.01% |
2017 Q4 | 44.9 Thousand USD | 0.0% |
2017 FY | 149.68 Thousand USD | 0.0% |
2017 Q3 | 44.9 Thousand USD | 0.0% |
2017 Q2 | 44.9 Thousand USD | 199.99% |
2017 Q1 | 14.96 Thousand USD | -99.34% |
2016 Q2 | - USD | 0.0% |
2016 Q4 | 2.27 Million USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q1 | - USD | 100.0% |
2016 FY | - USD | -100.0% |
2015 FY | 194.49 Thousand USD | 0.0% |
2015 Q4 | -194.49 Thousand USD | -424.93% |
2015 Q3 | 59.85 Thousand USD | -22.26% |
2015 Q2 | 77 Thousand USD | 33.6% |
2015 Q1 | 57.63 Thousand USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AIM ImmunoTech Inc. | 202 Thousand USD | -442.574% |
Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
Armata Pharmaceuticals, Inc. | 4.52 Million USD | 75.8% |
Actinium Pharmaceuticals, Inc. | 81 Thousand USD | -1253.086% |
Azitra, Inc. | 686 Thousand USD | -59.767% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | -47.51% |
Chromocell Therapeutics Corporation | - USD | -Infinity% |
Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
CEL-SCI Corporation | - USD | -Infinity% |
iBio, Inc. | 225 Thousand USD | -387.111% |
Lineage Cell Therapeutics, Inc. | 8.94 Million USD | 87.747% |
MAIA Biotechnology, Inc. | - USD | -Infinity% |
Navidea Biopharmaceuticals, Inc. | 65.65 Thousand USD | -1569.408% |
NovaBay Pharmaceuticals, Inc. | 14.72 Million USD | 92.557% |
NanoViricides, Inc. | - USD | -Infinity% |
Oragenics, Inc. | 37.65 Thousand USD | -2810.791% |
BiomX Inc. | -357 Thousand USD | 407.003% |
BiomX Inc. | -357 Thousand USD | 407.003% |
Protalix BioTherapeutics, Inc. | 65.49 Million USD | 98.327% |
Palatin Technologies, Inc. | 4.49 Million USD | 75.591% |
Scorpius Holdings, Inc. | 6.99 Million USD | 84.331% |